PHL-TERBINAFINE TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
12-10-2016
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
TERBINAFINE (TERBINAFINE HYDROCHLORIDE)
Tillgänglig från:
PHARMEL INC
ATC-kod:
D01BA02
INN (International namn):
TERBINAFINE
Dos:
250MG
Läkemedelsform:
TABLET
Sammansättning:
TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
ALLYLAMINES
Produktsammanfattning:
Active ingredient group (AIG) number: 0132855002; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2016-10-25
Produktens egenskaper
PRODUCT MONOGRAPH
PR
PHL-TERBINAFINE
Terbinafine Tablets, USP
250 mg Terbinafine, as Terbinafine Hydrochloride
ANTIFUNGAL AGENT
PHARMEL INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
October 03, 2016
SUBMISSION CONTROL NO.: 197968
_ _
_phl-TERBINAFINE Product Monograph _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................3
INDICATIONS AND CLINICAL USE
....................................................................................3
CONTRAINDICATIONS
.........................................................................................................3
WARNINGS AND PRECAUTIONS
........................................................................................4
ADVERSE REACTIONS
.........................................................................................................7
DRUG INTERACTIONS
........................................................................................................
10
DOSAGE AND ADMINISTRATION
....................................................................................
13
OVERDOSAGE
.....................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 14
STORAGE AND STABILITY
................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 15
PART II: SCIENTIFIC INFORMATION
...........................................................................
16
PHARMACEUTICAL INFORMATION
................................................................................
16
CLINICAL TRIALS
..........................................................................................
Läs hela dokumentet
